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Abstract
Background: The purpose of this study was to investigate the impact of histology on survival stratified by the
Graded Prognostic Assessment (GPA) for non-small cell lung cancer (NSCLC) in a group of selected patients
treated recently.
Methods: A total of 171 NSCLC patients with brain metastases treated by hypofractionated stereotactic
radiotherapy with or without whole-brain radiotherapy between 2001 and 2011 were included. The GPA score
was calculated for each patient. Tumor histologies were categorized into adenocarcinoma (ADCA) and non-
ADCA. Median survival time (MST, in months) was calculated using the Kaplan-Meier method. The log-rank test
was used to determine statistical differences.
Results: MSTs by histology were: ADCA 15 (n = 92) and non-ADCA 10 (n = 79) (p < 0.001). For all patients, the
MSTs by GPA score were: GPA 3.5-4, 24; GPA 2.5-3, 15; GPA 1.5-2, 9 and GPA 0-1, 6 (p < 0.001). The histology of
ADCA showed a statistically significant higher MST than non-ADCA for patients with GPA 2.5-4. For GPA 2.5-3,
MSTs were: ADCA 18, non-ADCA 10 (p = 0.007); for GPA 3.5-4, MSTs were: ADCA 30, non-ADCA 17 (p = 0.046). For
GPA 0-2, MSTs did not differ significantly by histology. For GPA 0-1, MSTs were: ADCA 8, non-ADCA 4 (p = 0.146);
GPA 1.5-2, MSTs were: ADCA 10, non-ADCA 8 (p = 0.291). We further found that non-ADCA in upper GPA class (3.
5–4) had similar survival with ADCA in lower GPA class (2.5–3) (MSTs were 17 and 18, respectively, p = 0.775). This
phenomenon also happened between patients of non-ADCA in upper GPA class (2.5–3) and those of ADCA in
lower GPA class (1.5–2) (MSTs were both 10, p = 0.724).
Conclusions: We confirmed that the histology of NSCLC had effect on the GPA in these selected patients treated
recently. ADCA showed a statistically significant higher MST than non-ADCA with GPA 2.5-4. The non-ADCA in upper
GPA classes (3.5-4 and 2.5-3) had similar survival to ADCA in lower GPA classes (2.5-3 and 1.5-2, respectively). The
histology as a new factor should be added to the original GPA for NSCLC.
Keywords: Brain metastases, Non-small cell lung cancer, Graded prognostic assessment, Histology, Hypofractionated
stereotactic radiotherapy
* Correspondence: 13804058616@163.com; sy_liguang@163.com
Department of Radiation Oncology, The First Affiliated Hospital of China
Medical University, 155 North Nanjing Street, Heping District, Shenyang
110001, Liaoning, China
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ma et al. Radiation Oncology  (2016) 11:92 
DOI 10.1186/s13014-016-0667-x
Background
Today, it is clear that the prognostic factors are different
in patients with brain metastases. To predict those who
have better survival in all patients, many different prog-
nostic indices have been developed [1–5]. The Graded
Prognostic Assessment (GPA) is a newer prognostic
index [4] and is less subjective and more quantitative
than the widely used Recursive Partitioning Analysis
(RPA) [1]. It incorporated number of brain metastases
which was of proven significance in the RTOG 9508 trail
and excluded the estimation of primary tumor control
which is subjective and difficult to quantify. The GPA
was refined with diagnosed-specific prognostic indices
for patients with brain metastases from some different
site or histology [6, 7]. The non-small cell lung cancer
(NSCLC) specific GPA index was a 4-titered prognostic
index. It is the sum of scores (0, 0.5, and 1.0) for four
factors (age, Karnofsky Performance Scale (KPS), num-
ber of brain metastases and presence of extracranial me-
tastases) (Table 1) [6, 7]. The histology of NSCLC as an
independent prognostic factor for patients with brain
metastases had been reported [8–10], while its effect on
the GPA index was not well defined. Guo et al. analyzed
a group of unselected patients with NSCLC brain metas-
tases treated from 1982 to 2004, they found that adeno-
carcinoma (ADCA) had a better survival time than other
histologies for patients with GPA 0-3 [11]. Although the
study of Guo et al. makes us notice the effect of hist-
ology on the GPA, there are still some questions need to
be answered. 1. The conclusions of Guo et al. are based
on the patients treated in an earlier treatment period
(1982–2004), whether these conclusions changed in re-
cent years? 2. Whether these conclusions still exist in se-
lected patients? 3. Whether the histology has other
effects on the GPA? To answer these questions and fur-
ther investigate the impact of histology on survival
stratified by the GPA we analyzed a group of selected
patients with brain metastases from NSCLC treated re-
cently in our institution.
Methods
Patient population
The present study was based on the data from patients
with brain metastases treated by hypofractionated stereo-
tactic radiotherapy (HSRT) with or without whole-brain
radiotherapy (WBRT) in our institution. Those newly di-
agnosed patients from pathologically confirmed NSCLC
were included. These patients did not receive other
treatments before their brain metastases were diag-
nosed. From April 2001 to September 2011, 171 pa-
tients were included in this study. There were 92
patients with ADCA and 79 patients with non-ADCA
(squamous cell carcinoma (SCC): 49, large-cell carcin-
oma (LCC): 10, other styles: 20). The characteristics are
listed in Table 2.
Table 1 Details of the GPA for NSCLC [6, 7]
GPA score
0 0.5 1.0
Age >60 50–60 <50
KPS <70 70–80 90–100
No. of brain metasases >3 2–3 1
Extracranial metastases present - absent
Table 2 Patient and treatment characteristics













< 50 38 22.2
50–60 50 29.2
> 60 83 48.6
KPS
< 70 32 18.7
70–80 82 48.0
90–100 57 33.3
No. of brain metastases
1 83 48.6
2–3 57 33.3










HSRT +WBRT 117 68.4
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HSRT
The HSRT process has been described before [12] and
as follows. A non-invasive mask was used to immobilize
patients. The helical computed tomography and mag-
netic resonance images were fused by image fusion soft-
ware. The gross tumor volume (GTV) was defined as
the contrast-enhanced tumor. The planning tumor vol-
ume (PTV) was defined by adding a 1-mm margin to
the GTV. Brainlab’s stereotactic treatment planning sys-
tem and SCAN 4.05 version of the three-dimensional
positioning and target system were applied to calculate
dose. The prescribed dose was delivered to the 80–90 %
dose line, which included more than 98 % of the PTV.
The common dose was 32Gy/4f, delivered every other
day. This method of dose administration was based on
two previous studies [13, 14]. Of course, the dose pre-
scription and fractions varied due to the size, location,
number of lesions and whether WBRT was given. Irradi-
ation was performed with 6-MV photons from a liner
accelerator (Siemens PRIMUS-M Germany) using mul-
tiple non-coplanar arcs. HSRT was performed alone in
54 patients and was combined with WBRT in 117 pa-
tients. For those patients treated combining with WBRT
(planning dose was 40Gy/20f, 5f/week) the time interval
was within 1 week before or after HSRT.
Statistical analysis
The GPA score was calculated for each patient. Tumor
histologies were categorized into ADCA and non-
ADCA. Overall survival was estimated using the Kaplan-
Meier method. Median survival time (MST, in months)
was calculated from the date of brain metastases diagno-
sis to the date of death. The log-rank test was used to
determine whether significant survival differences were
present among patient groups. A p value <0.05 was
considered statistically significant. Analyses were per-
formed using SPSS, version 13.0 (SPSS Inc).
Results
At the end of December 2014, 155 patients (90.6 %) had
died. For 171 patients, the median follow-up time was
13 months (range 1–116 months). The MST for all pa-
tients was 13 months (95 % CI 11.258–14.742 months).
The median age was 59 years (range 25–80 years). The
median KPS was 80 (range 60–100). The median num-
ber of lesions at diagnosis was 2 (range 1–8).
MSTs by histology were: ADCA 15 (n = 92) and non-
ADCA 10 (n = 79) (p < 0.001) (Fig. 1). For all patients,
the MSTs by GPA score were: GPA 3.5-4, 24; GPA 2.5-3,
15; GPA 1.5-2, 9 and GPA 0-1, 6 (p < 0.001) (Fig. 2).
The histology of ADCA showed a statistically significant
higher MST than non-ADCA for patients with GPA 2.5-4.
For GPA 2.5-3, MSTs were: ADCA 18, non-ADCA 10 (p =
0.007); for GPA 3.5-4, MSTs were: ADCA 30, non-ADCA
17 (p = 0.046). For GPA 0-2, MSTs did not differ signifi-
cantly by histology. For GPA 0-1, MSTs were: ADCA 8,
non-ADCA 4 (p = 0.146); GPA 1.5-2, MSTs were: ADCA
10, non-ADCA 8 (p = 0.291) (Fig. 3).
We further found that non-ADCA in upper GPA class
(3.5-4) had similar survival with ADCA in lower GPA
class (2.5-3) (MSTs were 17 and 18, respectively, p =
0.775). This phenomenon also happened between pa-
tients of non-ADCA in upper GPA class (2.5-3) and
those of ADCA in lower GPA class (1.5-2) (MSTs were
both 10, p = 0.724) (Fig. 4).
Discussion
Although the GPA has been validated in different
NSCLC groups [6, 7, 15, 16], the effect of histology on
























Fig. 1 Overall survival for patients with brain metastases from non-small cell lung cancer by histology



























Fig. 2 Overall survival for patients with brain metastases from non-small cell lung cancer by graded prognostic assessment group
Fig. 3 Overall survival for patients with brain metastases from non-small cell lung cancer by histology and by graded prognostic assessment group
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Nieder et al. analyzed 209 patients with brain me-
tastases from NSCLC treated with different methods
(radiosurgery, surgical resection, WBRT, best support-
ive care) and found that ADCA histology is an inde-
pendent prognostic factor in different multivariate
models [8]. They also analyzed the histology and the
GPA index together in a multivariate model and
found that both factors remain statistically significant
[8]. In their study the patients with ADCA had sig-
nificantly longer MST than those with non-ADCA
(SCC or LCC). In a previous study which included
the same patient population of the present study we
found that histology (non-ADCA vs ADCA) was an
independent prognostic factor (HR 1.606 95 % CI
1.138–2.267, p = 0.007) besides those factors in the
GPA (age, KPS, number of brain metastases and pres-
ence of extracranial metastases) [12]. These results
suggested that histology of NSCLC should be taken
into account when using the GPA index.
Guo et al. evaluated the impact of histology on sur-
vival of patients with NSCLC brain metastases stratified
by the GPA. They analyzed a group of unselected pa-
tients (treated by WBRT, radiosurgery, or surgery) in a
earlier period (1982–2004) and found that ADCA had a
statistically significant higher MST than other histologies
in patients with GPA 0-3 [11]. In the present study we
observed a similar phenomenon in our selected patients
(treated by HSRT with or without WBRT) in recent
years (2001–2011), but the survival advantage of ADCA
only existed in patients with GPA 2.5-4. Although there
were some differences between the present study and
that of Guo et al., both studies had a similar conclusion:
the patients of ADCA had a statistically significant lon-
ger survival time than other histologies of NSCLC in
Fig. 4 Overall survival for patients with brain metastases from non-small cell lung cancer who had similar median survival time
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some GPA classes. We further found that non-ADCA in
two upper GPA classes (3.5-4 and 2.5-3) had similar sur-
vival to ADCA in their lower GPA classes (2.5-3 and
1.5-2, respectively). Our results suggested that the hist-
ology as a new factor should be added to the original
GPA for NSCLC. For example, if ADCA is set to 1 and
non-ADCA is set to 0, the patients of non-ADCA with
original GPA 3.5-4 and those patients of ADCA with
original GPA 2.5-3 will have the same new score 3.5-4,
at the same time the patients of ADCA with original
GPA 3.5-4 will have the new score 4.5-5, then not only
these patients who had better survival could be distin-
guished but also those who had similar MST will be
merged. Because our suggestion was based on a single-
institution retrospective study, whether it is possible to
use the adapted GPA score in other patient populations
needs to be further investigated.
Many studies had reported that ADCA had better sur-
vival than other subtypes of NSCLC [8–10, 17], while
the reasons are still controversial. One main controversy
is whether new systemic drugs, especially targeted ther-
apies, are causes for the survival advantage of ADCA.
In a study which included unselected NSCLC brain me-
tastases patients treated with different methods be-
tween 1990 and 2011, Nieder et al. found that patients
with ADCA had significantly longer survival (p = 0.019,
the absolute difference in MST was 0.5 months) even
in an earlier period (1990–2003) when pemetrexed and
EGFR tyrosine kinase inhibitors were not available [8].
The absolute differences became much larger later
(2004–2011). MST in patients with ADCA increased from
2.5 to 6.8 months (p = 0.039). In SCC, an increase from 2.0
to 3.3 months could be observed (p = 0.430) [8]. Kuremsky
et al. analyzed the data of patients treated with Gamma
Knife radiosurgery between 2000 and 2010 and found that
ADCA had a survival advantage over SCC (MSTs were
10.2 and 5.3 months, respectively, p = 0.008) [9]. To further
investigate the possible causes for this difference, they
compared the outcomes for patients treated before and
after 2005. Their results showed no differences in the rates
of local control (p = 0.58), distant brain failure (p = 0.48),
or the overall survival (p = 0.64) between the two cohorts
[9]. We also analyzed the possible effect of treatment pe-
riods on the survival advantage of ADCA and got similar
results to that of Kuremsky et al. In non-ADCA there was
no difference of survival time between two treatment pe-
riods (10 months for 2001–2004 and 9 months for 2005–
2011, p = 0.593). Although an increase of MST from 13 to
17 months was observed in ADCA since 2005, there was
no statistically significance (p = 0.090).
Finally, the limitations of our study should be men-
tioned: 1. As a single-institution study the sample size is
small; 2. The retrospective nature of this study is prone to
bias; 3. We could not confirm the causes of survival
advantage of ADCA for absence of data on gene muta-
tions. We suggest that multi-institution prospective stud-
ies be performed to further assess the effect of histology
and to confirm the causes for this effect in the future.
Conclusions
We confirmed that the histology had effect on the GPA in
these patients with brain metastases from NSCLC treated
by HSRT with or without WBRT. ADCA showed a statis-
tically significant higher MST than non-ADCA with GPA
2.5-4. The non-ADCA in upper GPA classes (3.5-4 and
2.5-3) had similar survival to ADCA in lower GPA classes
(2.5-3 and 1.5-2, respectively). The histology as a new fac-
tor should be added to the original GPA for NSCLC.
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